How short telomeres and telomerase reactivation drive liver scarring and cancer

Telomere dysfunction and telomerase reactivation in the etiology and progression of liver cancer

NIH-funded research Washington University · NIH-11248004

This project looks at how short telomeres and reactivated telomerase cause liver scarring and hepatocellular carcinoma using human stem-cell models to help people at risk of liver cancer.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionWashington University NIH-funded
Lab location1 site (Saint Louis, United States)
Project IDNIH-11248004 on NIH RePORTER

What this research studies

Researchers will grow human pluripotent stem cells engineered to carry telomerase mutations or shortened telomeres and turn them into different types of liver cells to mimic disease. They will compare matched cells with and without TERT promoter mutations to see whether telomerase reactivation helps damaged liver cells survive or become cancerous. The team will measure DNA damage signals and the signaling pathways that lead to cell failure, scarring, and tumor formation. Results aim to point to markers or molecular targets that could guide future prevention or treatment strategies for telomere-related liver disease.

Who could benefit from this research

Good fit: People most relevant to this work include those with liver fibrosis, familial telomerase or telomere disorders, or early-stage hepatocellular carcinoma suspected to involve telomere dysfunction.

Not a fit: Patients whose liver disease is driven by causes unrelated to telomere dysfunction (for example, some viral, metabolic, or autoimmune conditions) may not receive direct benefit from these findings.

Why it matters

Potential benefit: If successful, this work could identify new markers or therapeutic targets to prevent or treat liver fibrosis and hepatocellular carcinoma linked to telomere damage.

How similar studies have performed: Mouse models support the importance of telomere maintenance for liver health, but using human pluripotent stem-cell models to study telomerase reactivation and transformation in liver cells is a newer and less-tested approach.

Where this research is happening

Saint Louis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cellular injury
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.